Vaccines

Introduction

Vaccines: biological preparations inducing adaptive immunity against pathogens. Core components: antigens, adjuvants, stabilizers. Purpose: prevent infectious diseases, reduce morbidity and mortality. Scope: prophylactic and therapeutic applications. Impact: global health, eradication of smallpox, control of polio, measles, influenza, COVID-19.

"Vaccination is the cornerstone of modern preventive medicine and a triumph of biotechnology." -- Stanley A. Plotkin

History of Vaccines

Early Developments

Variolation: 10th century China, deliberate exposure to smallpox scabs. Edward Jenner (1796): cowpox inoculation, first modern vaccine. Pasteur's contributions: rabies (1885), cholera vaccines.

20th Century Expansion

Polio vaccines: Salk (inactivated, 1955), Sabin (oral live attenuated, 1961). DTP (diphtheria, tetanus, pertussis) combination vaccines. Advancements in culturing viruses, bacterial polysaccharide vaccines.

Modern Era

Recombinant DNA technology: hepatitis B vaccine (1986). Conjugate vaccines: pneumococcal, meningococcal. mRNA and viral vector vaccines: COVID-19 pandemic accelerated development.

Types of Vaccines

Live Attenuated Vaccines

Definition: weakened pathogens retaining replication ability. Examples: measles, mumps, rubella (MMR), varicella. Pros: strong cellular and humoral immunity. Cons: contraindicated in immunocompromised.

Inactivated Vaccines

Definition: killed pathogens, incapable of replication. Examples: inactivated polio vaccine, hepatitis A. Pros: safer, stable. Cons: weaker immune response, require boosters.

Subunit Vaccines

Definition: purified antigenic components (proteins, polysaccharides). Examples: hepatitis B, HPV vaccines. Pros: targeted immunity, fewer side effects. Cons: may need adjuvants.

mRNA Vaccines

Definition: lipid nanoparticle-encapsulated mRNA encoding antigen. Examples: Pfizer-BioNTech, Moderna COVID-19 vaccines. Mechanism: host cells produce antigen in situ. Advantages: rapid design, scalable production.

Viral Vector Vaccines

Definition: recombinant viral vectors delivering antigen genes. Examples: AstraZeneca, Johnson & Johnson COVID-19 vaccines. Pros: induce robust immunity, stable. Cons: pre-existing vector immunity possible.

Toxoid Vaccines

Definition: inactivated bacterial toxins. Examples: diphtheria, tetanus. Mechanism: neutralizing antibodies against toxins.

Conjugate Vaccines

Definition: polysaccharide antigens linked to protein carriers. Examples: Hib, pneumococcal conjugate vaccines. Enhance immunogenicity in infants.

Mechanism of Action

Antigen Recognition

Antigen-presenting cells (APCs) uptake vaccine antigens. Processing and presentation via MHC I and II molecules. Activation of naïve T cells.

Humoral Immunity

B cell activation, differentiation into plasma cells. Antibody production: neutralization, opsonization, complement activation.

Cell-mediated Immunity

CD8+ cytotoxic T lymphocytes destroy infected cells. CD4+ helper T cells coordinate immune responses.

Memory Formation

Generation of memory B and T cells. Rapid, enhanced response upon subsequent exposure.

Herd Immunity

Population-level protection by reducing pathogen transmission. Threshold depends on R0 and vaccine coverage.

Vaccine Development Process

Preclinical Studies

In vitro and animal model testing. Assess immunogenicity, safety, dosage. Identification of candidate antigens.

Clinical Trials

Phase I: safety, dosage in small cohorts. Phase II: immunogenicity, expanded safety. Phase III: efficacy, large populations, diverse demographics.

Regulatory Approval

Submission of trial data to agencies (FDA, EMA). Review of manufacturing quality, safety, efficacy. Post-approval surveillance.

Post-Market Surveillance

Monitoring adverse events, long-term immunity. Phase IV studies, vaccine effectiveness in real-world settings.

Biotechnological Advances

Recombinant DNA Technology

Cloning antigen genes in expression systems (yeast, bacteria). Purification of recombinant proteins. Examples: hepatitis B surface antigen.

mRNA Technology

In vitro transcription of antigen-encoding mRNA. Lipid nanoparticle delivery systems. Rapid adaptability to emerging pathogens.

Viral Vector Engineering

Modification of adenoviruses, poxviruses for antigen delivery. Balancing immunogenicity and safety.

Nanoparticle Vaccines

Self-assembling protein nanoparticles, virus-like particles (VLPs). Enhanced antigen presentation, multivalency.

Reverse Vaccinology

Genome-based antigen discovery using bioinformatics. Identification of novel vaccine targets.

Adjuvants and Formulations

Purpose of Adjuvants

Enhance immune response magnitude and duration. Promote antigen uptake and presentation.

Common Adjuvants

Aluminum salts (alum): depot effect, inflammasome activation. MF59: squalene oil-in-water emulsion. AS03: similar to MF59 with α-tocopherol.

Novel Adjuvants

Toll-like receptor agonists (CpG, MPL). Stimulate innate immunity selectively.

Formulation Types

Liquid, freeze-dried (lyophilized), emulsions. Stabilizers: sugars, proteins to preserve integrity.

Combination Adjuvants

Synergistic mixtures targeting multiple immune pathways. Examples: AS04 (alum + MPL).

Production Methods

Cell Culture Systems

Mammalian cells (CHO, Vero): viral propagation, recombinant protein expression. Yeast and bacterial cultures for subunits.

Egg-Based Production

Embryonated chicken eggs for influenza virus growth. Limitations: time-consuming, egg allergies.

Bioreactors and Fermentation

Scale-up of cell cultures under controlled conditions. Monitoring parameters: pH, oxygen, temperature.

Purification Techniques

Chromatography (affinity, ion exchange), ultrafiltration. Removal of contaminants, endotoxins.

Quality Control

Potency assays, sterility tests, endotoxin levels, stability studies.

Efficacy and Safety

Measuring Vaccine Efficacy

Endpoints: infection reduction, disease severity, transmission blocking. Statistical analysis: relative risk reduction, number needed to vaccinate.

Factors Affecting Efficacy

Pathogen variability, host genetics, immune status, vaccine storage and administration.

Safety Profiles

Common adverse events: injection site pain, fever, mild systemic symptoms. Rare events: anaphylaxis, Guillain-Barré syndrome.

Pharmacovigilance

Surveillance systems (VAERS, EudraVigilance). Signal detection, risk-benefit analysis.

Risk Communication

Public education, addressing vaccine hesitancy, transparent reporting.

Distribution and Storage

Cold Chain Requirements

Temperature control: 2°C to 8°C for most vaccines. Ultralow temperatures (-70°C) for mRNA vaccines. Importance: maintain potency, prevent degradation.

Packaging and Transport

Use of insulated containers, temperature monitors. Logistics coordination, especially in low-resource settings.

Vaccine Wastage

Causes: cold chain failures, expiration, multi-dose vial wastage. Impact: economic loss, reduced coverage.

Innovations in Storage

Thermostable formulations, lyophilized vaccines. Novel delivery devices (microneedle patches).

Global Distribution Challenges

Infrastructure deficiencies, conflicts, vaccine nationalism. Strategies: COVAX, partnerships with NGOs.

Challenges and Future Prospects

Emerging Pathogens

Rapid identification and vaccine design against novel viruses (e.g., SARS-CoV-2, Zika). Need for universal vaccines.

Vaccine Hesitancy

Social, cultural, misinformation barriers. Strategies: education, community engagement, policy enforcement.

Technological Innovations

Next-gen platforms: self-amplifying RNA, DNA vaccines, synthetic biology. Personalized vaccines for cancer and chronic diseases.

Global Access and Equity

Bridging disparities in vaccine availability. Strengthening local manufacturing and distribution.

Durability and Boosting

Improving longevity of immunity. Development of broad-spectrum, multivalent vaccines.

Vaccine Development Timeline:1. Antigen discovery → 2. Preclinical testing → 3. Phase I trial (n~20-100) → 4. Phase II trial (n~100-500)→ 5. Phase III trial (n~thousands) → 6. Regulatory approval → 7. Manufacturing scale-up → 8. Post-market surveillance

References

• Plotkin, S.A., Orenstein, W.A., Offit, P.A. Vaccines. 7th ed. Elsevier Saunders; 2018.
• Krammer, F. SARS-CoV-2 vaccines in development. Nature. 586(7830), 2020, pp. 516-527.
• Rappuoli, R., Aderem, A. A 2020 vision for vaccines against HIV, tuberculosis, and malaria. Nature. 473(7348), 2011, pp. 463-469.
• Poland, G.A., Ovsyannikova, I.G., Kennedy, R.B. Personalized vaccinology: A review. Vaccine. 36(36), 2018, pp. 5350-5357.
• Delany, I., Rappuoli, R., De Gregorio, E. Vaccines for the 21st century. EMBO Mol Med. 5(6), 2013, pp. 705-707.